This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Spikevax | |
|---|---|
| Name | Spikevax |
| Type | mRNA |
| Target | SARS-CoV-2 |
| Inventor | Moderna |
| Developer | Moderna, National Institute of Allergy and Infectious Diseases |
| Routes of administration | Intramuscular |
Spikevax Spikevax is a messenger RNA vaccine for prevention of COVID-19 developed by Moderna in collaboration with the National Institute of Allergy and Infectious Diseases, with manufacturing and distribution partnerships involving Lonza Group, Catalent, GlaxoSmithKline and national programs such as Operation Warp Speed, European Commission procurement, and initiatives by the World Health Organization. The vaccine was evaluated in multinational clinical trials at sites including the NIH Clinical Center, centers in Boston, Massachusetts, Los Angeles, California, and trial networks linked to institutions like Johns Hopkins University, Massachusetts General Hospital, and the Fred Hutchinson Cancer Center.
Spikevax is indicated for active immunization to prevent symptomatic infection and severe disease caused by SARS-CoV-2 in adults and authorized pediatric populations; recommendations for use have been issued by agencies such as the Food and Drug Administration, the European Medicines Agency, and the World Health Organization. Public health deployment has been coordinated with national bodies including the Centers for Disease Control and Prevention, the Public Health Agency of Canada, the UK Health Security Agency, and mass vaccination campaigns in countries like United States, Canada, United Kingdom, Germany, and Japan.
The vaccine contains nucleoside-modified synthetic mRNA encoding the prefusion stabilized spike protein of SARS-CoV-2, formulated in lipid nanoparticles comprising proprietary lipids and excipients produced with partners such as Duke University spinouts and suppliers in Switzerland and Belgium. The lipid nanoparticle platform shares technological lineage with academic work from laboratories at Harvard University, University of Pennsylvania, and collaborations with the National Institutes of Health; vials contain buffers and cryoprotectants compatible with storage guidance issued by regulatory bodies in Italy and Spain.
Manufacturing scaling relied on contract manufacturing organizations including Lonza Group, Catalent, Thermo Fisher Scientific, and fill–finish sites in Belgium, Mexico, and Switzerland; distribution has used logistics networks coordinated by the European Commission, the Department of Defense (United States), and nongovernmental partners like Médecins Sans Frontières for global allocation. Cold-chain management incorporated ultra-low-temperature freezers supplied by companies such as Pfizer-associated vendors, national storage programs in Canada and Australia, and transport by carriers including UPS and FedEx under agreements negotiated with ministries in France and Brazil.
Phase I, II, and III trials were conducted under protocols overseen by institutional review boards at Beth Israel Deaconess Medical Center, Vanderbilt University Medical Center, and trial networks coordinated with the National Institute of Allergy and Infectious Diseases; the pivotal phase III trial, known as COVE, enrolled tens of thousands of participants across sites in the United States and reported high efficacy against symptomatic COVID-19 in interim analyses submitted to the Food and Drug Administration and the European Medicines Agency. Efficacy estimates were compared with contemporaneous vaccine trials by developers such as Pfizer–BioNTech, and observational effectiveness studies involved datasets from health systems like Kaiser Permanente and national registries in Israel and Scotland.
Reported adverse events in trials and post-authorization surveillance included local injection-site reactions and systemic events such as fatigue, headache, myalgia and fever, with safety monitoring coordinated by agencies like the Vaccine Adverse Event Reporting System, the European Medicines Agency pharmacovigilance network, and the World Health Organization’s Global Advisory Committee on Vaccine Safety. Rare events under investigation involved myocarditis and pericarditis reported in surveillance from Israel and the United States military health system, with risk-benefit assessments informed by expert panels at the Advisory Committee on Immunization Practices and specialist organizations such as the American Heart Association.
Spikevax received emergency use authorizations, conditional marketing authorizations, and full approvals from regulators including the Food and Drug Administration, the European Medicines Agency, Health agencies in Japan and Australia, and guidance for use from the World Health Organization. National immunization technical advisory groups in countries such as Germany, France, Italy, and Canada issued prioritization and dosing interval recommendations informed by data from the COVE trial and real-world effectiveness studies published in journals affiliated with institutions like Johns Hopkins University and Imperial College London.
Development emerged from foundational mRNA research by teams at Moderna, backed by funding from the Biomedical Advanced Research and Development Authority, collaborations with the National Institute of Allergy and Infectious Diseases under leadership associated with researchers like Anthony Fauci at the NIH, and industrial partnerships for scale-up with Lonza Group and contract manufacturers in Switzerland and Spain. Clinical development occurred in parallel with other vaccine efforts by companies such as Pfizer–BioNTech, AstraZeneca, and Johnson & Johnson, and its rollout intersected with global initiatives like COVAX and national programs like Operation Warp Speed.